Tyme Technologies (NASDAQ:TYME)‘s stock had its “buy” rating restated by analysts at Canaccord Genuity in a research note issued on Monday, AnalystRatings.com reports.
Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $9.50 target price on shares of Tyme Technologies in a research report on Thursday, May 21st. Zacks Investment Research downgraded shares of Tyme Technologies from a “buy” rating to a “hold” rating in a research report on Friday, May 29th.
Tyme Technologies stock opened at $1.38 on Monday. The company has a market capitalization of $153.55 million, a P/E ratio of -7.67 and a beta of 0.97. The business has a 50 day moving average of $1.46 and a 200-day moving average of $1.32. Tyme Technologies has a 1 year low of $0.86 and a 1 year high of $2.04.
Tyme Technologies (NASDAQ:TYME) last released its earnings results on Wednesday, May 20th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. As a group, equities research analysts predict that Tyme Technologies will post -0.28 EPS for the current fiscal year.
In other Tyme Technologies news, major shareholder Michael Demurjian sold 20,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $1.36, for a total transaction of $27,200.00. Following the transaction, the insider now directly owns 23,718,546 shares in the company, valued at approximately $32,257,222.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 240,000 shares of company stock worth $328,600 over the last 90 days. Company insiders own 27.17% of the company’s stock.
Several institutional investors have recently bought and sold shares of TYME. Renaissance Technologies LLC bought a new position in shares of Tyme Technologies during the 4th quarter worth approximately $25,000. Advisor Group Holdings Inc. bought a new position in shares of Tyme Technologies during the 1st quarter worth approximately $28,000. Citigroup Inc. boosted its holdings in shares of Tyme Technologies by 72.2% during the 4th quarter. Citigroup Inc. now owns 23,556 shares of the company’s stock worth $33,000 after buying an additional 9,873 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Tyme Technologies by 12,625.0% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,450 shares of the company’s stock worth $36,000 after purchasing an additional 25,250 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Tyme Technologies by 31.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 42,232 shares of the company’s stock worth $59,000 after purchasing an additional 10,124 shares in the last quarter. Hedge funds and other institutional investors own 11.84% of the company’s stock.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Further Reading: Stock Symbols and CUSIP Explained
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.